The significance of the work lies in a gap that many researchers know intimately but few publish about. Transgenic mouse models are among the most powerful tools in biomedical research, particularly for studying human neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis. Human studies of these conditions are constrained by ethical boundaries, limited access to living nervous tissue, and the slow, unpredictable timeline of disease progression. Mouse models, by contrast, allow scientists to control genetic background, disease timing, and dosage with precision, making it possible to watch neurodegeneration unfold step by step. Yet the tissues these studies depend on, such as specific brain regions or delicate nerve bundles, are notoriously difficult to obtain cleanly, and published extraction protocols have been few and far between.

The consequences of that scarcity are more than an inconvenience. When each laboratory, or even each technician within a laboratory, improvises its own dissection technique, the resulting tissue samples can differ in ways that have nothing to do with the biology under investigation. A brain region harvested with crushing forceps yields different protein profiles than one lifted gently with curved spatulas. A spinal cord contaminated by surrounding bone fragments or blood skews transcriptomic readouts. Cerebrospinal fluid collected too slowly or with the wrong angle of entry can be diluted or contaminated, invalidating biomarker measurements. These small procedural variations accumulate into the kind of irreproducible results that have plagued preclinical research for years, wasting animals, funding, and scientific effort.

The new paper addresses this by codifying five distinct procedures: whole brain extraction, brain microdissection, spinal cord extrusion, cerebrospinal fluid collection, and sciatic nerve dissection. Each protocol is written to be succinct and accessible, with a required materials list that specifies not just which instruments to use but how to use them properly. That level of operational detail matters. In microdissection, where a researcher may need to isolate the hippocampus or cortex from an intact brain, the difference between a clean separation and a mangled sample often comes down to tool selection, angle of cut, and the order of steps, all of which are now explicitly documented rather than passed along informally from senior technician to trainee.

Every protocol in the study was performed under biosafety level 2 guidelines, a precautionary standard comparable to the sterility practices required in human surgery. This is an important framing choice. Treating the dissection bench with surgical discipline, including appropriate personal protective equipment, sterile instruments, and controlled handling of biological material, protects both the researcher and the sample. It also reinforces a broader theme of the paper: the manual skills required for high-quality animal tissue dissection are directly transferable to clinical settings. A researcher who has learned to extract a mouse spinal cord without tearing the meninges is practicing the same careful tissue-handling instincts that a surgical trainee will one day need with patients.

The protocols were not developed in isolation. According to the authors, they were refined through feedback from numerous research studies in transcriptomics and pharmaceutical development, two fields where tissue quality is not merely desirable but decisive. Transcriptomic analyses, which measure the complete set of RNA transcripts in a sample, are exquisitely sensitive to post-mortem damage and handling artifacts; degraded or contaminated tissue produces gene expression profiles that can mislead an entire study. Pharmaceutical development, meanwhile, often depends on comparing treated and untreated animals across large cohorts, sometimes at multiple time points and across multiple sites. In both contexts, a dissection protocol that minimizes tissue damage and increases accuracy translates directly into cleaner data and more confident decisions about which drug candidates to advance.

The spinal cord extrusion technique deserves particular attention, because the spinal cord is among the most fragile structures a neuroscientist routinely handles. Encased in a bony vertebral column and surrounded by protective membranes, it resists casual extraction. Traditional approaches that involve cutting away vertebrae piece by piece are slow and risk damaging the cord itself. Extrusion, by contrast, uses hydraulic pressure to gently push the intact cord out of the vertebral canal, preserving its architecture for downstream analysis. By standardizing this procedure, the authors offer laboratories a faster, less traumatic alternative that can be learned and repeated consistently, even by relatively new members of a research team.

Cerebrospinal fluid collection presents its own challenges. The fluid bathes the brain and spinal cord and carries molecular signatures of neurological disease, making it a prized specimen for biomarker discovery. But it is produced in small volumes, and a clumsy collection attempt can yield blood-contaminated samples that render measurements useless. The protocol described in the paper specifies the materials, positioning, and technique needed to obtain clean samples reliably, addressing one of the most common sources of failed experiments in neurochemical research. Similarly, the sciatic nerve dissection protocol supports the growing field of peripheral neuropathy research, where the largest nerve in the mouse body serves as a accessible window into nerve damage, regeneration, and pain biology.

What makes this contribution potentially viral within the research community is its practicality. Rather than reporting a single novel finding, the paper delivers infrastructure: a set of well-defined, freely accessible procedures that any laboratory can adopt, teach, and audit. In an era when funding agencies and journals increasingly demand evidence of methodological rigor and reproducibility, such protocols function as a shared foundation. They reduce the training burden on new researchers, decrease the number of animals sacrificed to failed or compromised dissections, and allow results from different laboratories to be compared on equal footing. The authors emphasize that these benefits extend across cross-disciplinary areas, from basic neuroanatomy to translational drug development.

The broader lesson for science is that reproducibility is not only a statistical or computational problem; it begins with hands, tools, and tissue. By writing down, testing, and refining the craft knowledge that has long lived in the heads of experienced technicians, Crew, Seerley, McElroy, and Panter have turned tacit skill into citable method. For the thousands of laboratories worldwide that rely on mouse models of neurological disease, these five protocols offer something deceptively simple and profoundly valuable: the confidence that the tissue on the dissection tray is a faithful representative of the biology they set out to study, and that another laboratory, following the same steps, would arrive at the same starting point.

Subject of Research: Standardized dissection protocols for mouse neurological tissues to improve reproducibility in neurodegenerative disease research

Article Title: Neurological tissue dissection techniques in mouse models for reproducible scientific results: Brain, spinal cord, cerebrospinal fluid, and sciatic nerve

Article References: Crew, L., Seerley, A., McElroy, S., & Panter, A. G. (2026). Neurological tissue dissection techniques in mouse models for reproducible scientific results: Brain, spinal cord, cerebrospinal fluid, and sciatic nerve. PLOS One, 21(10), e0358771. https://doi.org/10.1371/journal.pone.0358771

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0358771

Keywords: mouse models, neuroscience, dissection protocols, reproducibility, brain microdissection, spinal cord, cerebrospinal fluid, sciatic nerve, transcriptomics, neurodegenerative disease, pharmaceutical development, PLOS One

The case centers on a patient who, after receiving CAR T cell therapy, developed signs of profound neurological injury. Brain magnetic resonance imaging revealed abnormalities characteristic of immune effector cell-associated neurotoxicity syndrome, universally abbreviated as ICANS: fluid-attenuated inversion recovery sequences showed periventricular white matter hyperintensities involving the atrium and temporal horn of the lateral ventricles, while diffusion-weighted imaging demonstrated areas of cytotoxic edema within the hippocampi on both sides. But what made the case exceptional was the spinal imaging. T2-weighted magnetic resonance images of the spine disclosed a longitudinally extensive spinal cord lesion, with abnormal signal intensity extending over more than three vertebral body segments. Critically, the lesion showed no enhancement after gadolinium administration on post-contrast T1-weighted images.

That combination of findings, a long spinal cord lesion that refuses to light up with contrast, is diagnostically treacherous. In clinical practice, a longitudinally extensive T2 hyperintense lesion in the spinal cord is nonspecific and can be produced by infectious, autoimmune, or vascular processes. Acute autoimmune inflammation of the spinal cord, or ischemia-related breakdown of the blood-spinal cord barrier, typically produces contrast enhancement, because the damaged barrier allows the gadolinium to leak into the cord tissue. A non-enhancing lesion therefore sits uneasily with the classic picture of acute inflammatory myelitis. The Paris team reasoned that, given the concurrent brain lesions suggestive of ICANS and the exclusion of infectious causes, the most likely diagnosis was spinal cord involvement as a component of ICANS itself, a manifestation so rare that only a handful of cases have been described in the literature, and those published reports describe similar non-enhancing imaging features.

The first and most urgent diagnostic step the authors emphasize is the systematic exclusion of infectious myelitis. This is not a bureaucratic precaution. Patients who have undergone CAR T cell therapy are profoundly immunocompromised, both from the lymphodepleting chemotherapy that precedes the infusion and from the therapy’s effects on normal B cells and other immune populations. In such patients, opportunistic infections of the central nervous system are a constant threat. The authors single out viral etiologies that must always be considered: cytomegalovirus, herpes simplex virus, varicella-zoster virus, enteroviruses, and human herpesvirus-6, each of which can produce devastating spinal cord disease in the immunosuppressed host. In their patient, cerebrospinal fluid cultures and multiplex polymerase chain reaction testing were negative, making an infectious etiology unlikely and clearing the way for the diagnosis of ICANS-associated myelopathy.

Understanding why this matters requires appreciating what ICANS is and how it usually behaves. Immune effector cell-associated neurotoxicity syndrome is the most feared non-hematological toxicity of CAR T cell therapy, typically emerging days after infusion as the engineered cells expand and release inflammatory cytokines. It usually announces itself with aphasia, confusion, tremor, and, in severe cases, seizures, cerebral edema, and coma. Aseptic meningitis is a common feature, and brain imaging may show transient abnormalities. The syndrome is graded from I to IV, with grade IV representing life-threatening neurotoxicity. Standard management escalates from corticosteroids to the interleukin-1 receptor antagonist anakinra for severe disease. But the spinal cord has been largely absent from this picture, which is precisely why the Paris case is so valuable to the field.

The timing of spinal cord involvement poses its own diagnostic puzzle, and the authors are candid about this uncertainty. In patients with severe ICANS, concomitant severe encephalopathy frequently precludes a complete neurological examination. A patient who is obtunded or comatose cannot report numbness, weakness, or a sensory level, and the examiner cannot reliably test for the signs that would localize a spinal cord lesion. As a result, it is often impossible to determine when spinal cord symptoms first occur, or whether they emerged before, alongside, or after the encephalopathy. In the reported patient, cerebral and spinal cord involvement probably developed simultaneously, a synchrony that itself supports the idea that both represent facets of a single systemic neurotoxic process rather than two independent complications.

Therapeutically, the patient received the recommended treatment for grade IV ICANS: high-dose corticosteroids combined with anakinra, the interleukin-1 receptor antagonist that has become the mainstay of salvage therapy for steroid-refractory neurotoxicity. Beyond this standard regimen, however, the evidence base evaporates. The authors state plainly that there is no clear evidence supporting a specific therapeutic strategy for ICANS-associated myelopathy. Interventions that neurologists might reach for in other forms of acute myelitis, such as intravenous immunoglobulins or plasmapheresis, have no established role here, because the underlying biology of the spinal cord lesion remains obscure. Larger case series, the authors argue, are needed to define the optimal treatment and the prognosis of this rare manifestation.

The imaging findings deserve close attention from clinicians who will face similar dilemmas. The pattern reported here, a long T2-hyperintense cord lesion without contrast enhancement, occurring in a patient with hippocampal cytotoxic edema and periventricular white matter changes, effectively constitutes a signature that others can look for. The hippocampal involvement is particularly suggestive, because bilateral cytotoxic edema in the hippocampi has been described in severe CAR T cell neurotoxicity and reflects the vulnerability of this region to the inflammatory and possibly vascular disturbances that ICANS produces. When such brain findings are accompanied by a non-enhancing longitudinal cord lesion in a recently infused patient, ICANS-associated myelopathy moves to the top of the differential diagnosis, provided infection has been rigorously excluded.

The broader significance of the case lies in the growing recognition that CAR T cell neurotoxicity is not confined to the brain. As the therapy expands from refractory lymphomas and multiple myeloma into earlier lines of treatment and into autoimmune diseases, the population of exposed patients is growing rapidly, and rare complications become clinically meaningful at scale. Reports such as this one, published as part of the journal’s imaging series with practical tips for intensivists, serve as sentinels. They alert critical care physicians, neurologists, and hematologists that when a CAR T cell recipient deteriorates neurologically, the evaluation must extend beyond the cranial vault. Spinal imaging, cerebrospinal fluid analysis with multiplex pathogen testing, and careful correlation of brain and cord findings should be part of the diagnostic armamentarium.

For now, the message from the Paris team is one of disciplined caution. Infectious myelitis must be systematically ruled out before attributing a cord lesion to ICANS, because the treatments differ fundamentally and the stakes are enormous. The non-enhancing character of the lesion, while atypical for classic autoimmune myelitis, appears consistent across the few published cases of ICANS-associated myelopathy and may reflect a distinct pathophysiology, perhaps one that does not disrupt the blood-spinal cord barrier in the way conventional inflammation does. Until larger series clarify the mechanism, the optimal treatment, and the long-term prognosis of this unusual complication, the case stands as both a warning and a guide: the engineered immune cells that save lives can, in rare instances, reach beyond the brain, and clinicians must be ready to recognize when they do.

Subject of Research: Acute myelopathy as a rare manifestation of CAR T cell therapy-associated neurotoxicity

Article Title: Acute myelopathy following chimeric antigen receptor (CAR) T cell therapy: an unusual diagnostic challenge

Article References: Bois, A., Provost, C., Decroocq, J., & Benghanem, S. (2026). Acute myelopathy following chimeric antigen receptor (CAR) T cell therapy: an unusual diagnostic challenge. Intensive Care Medicine. https://doi.org/10.1007/s00134-026-08617-w

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08617-w

Keywords: CAR T cell therapy, ICANS, neurotoxicity, myelopathy, spinal cord, immune effector cell, MRI, encephalopathy, anakinra, corticosteroids, immunocompromised, intensive care

Conjoined twins arise from aberrant embryogenesis in a monozygotic, monochorionic pregnancy, in which the developing embryos fail to separate completely. They are extraordinarily rare, with an estimated incidence of one in 100,000 to 250,000 births, and roughly half of affected pregnancies end in stillbirth. The condition occurs more frequently in females, at a ratio of approximately three to one. Classification depends on the site of fusion: thoracopagus twins are joined at the chest, omphalopagus at the abdomen, ischiopagus at the pelvis, craniopagus at the head, and pygopagus twins at the sacrum or rump. Pygopagus twins account for only about 6 to 19 percent of all conjoined twin cases, making them one of the rarer varieties. In pygopagus fusion, the twins typically share portions of the gastrointestinal and genitourinary systems, and in a small minority of cases the neural elements are involved as well. Of the pygopagus separations reported in the medical literature, shared dura has been documented in 17 cases and shared spinal cord in only 10, underscoring just how unusual the anatomy in this new case truly was.

The twins in this report were discovered during a routine prenatal ultrasound at 20 weeks of gestation, allowing the mother and her obstetricians to plan carefully for the delivery. Her antenatal course remained otherwise uneventful, and the babies were born by preplanned lower segment cesarean section at a government medical hospital, with a combined birth weight of 3.6 kilograms. The infants were fused at the lower body in the sacral region by a soft tissue bridge measuring roughly 10 centimeters across the skin. They were referred to a tertiary medical college two days after birth, where they were designated Twin A and Twin B. Baseline investigations showed stable physiological parameters in both infants, and echocardiography confirmed normal cardiac anatomy and function in each, with no shunt anomalies and normal pulmonary artery pressures. Abdominal ultrasound detected no significant abnormalities, meaning the twins did not share vital visceral organs, a factor that substantially improved their surgical prognosis.

When a multidisciplinary board of pediatric surgeons, neurosurgeons, pediatricians, anesthesiologists, and a dedicated pediatric clinical nutritionist convened to evaluate the pair, they reached a critical conclusion: the infants were simply too small and too underweight to withstand the physiological trauma of a prolonged separation surgery. Moreover, the skin and subcutaneous tissue surrounding the conjoined pelvic junction were judged insufficient for tension-free primary closure. Rather than rushing to the operating room, the board opted for a delayed elective approach, instituting a structured nutritional rehabilitation program supervised by the clinical nutritionist. The twins received maternal breastfeeding supplemented with calorie-dense nutrition, with a target weight gain velocity of 20 to 30 grams per day per infant. Over the following months, their combined weight climbed to 8.9 kilograms, and biochemical markers confirmed that they had built sufficient physiological reserves to tolerate intraoperative blood loss, lengthy anesthesia, and the hypercatabolic stress of post-surgical healing.

The delay also served a second, equally important purpose: it allowed natural somatic growth to generate the redundant skin needed for reconstruction. The team had formally considered inserting mechanical tissue expanders, devices commonly used to stretch skin before complex closures. They ultimately rejected this option for three reasons: stringent institutional resource limitations, the heightened risks of expander erosion, hematoma, and catastrophic implant infection given the proximity to the diaper and perineal region, and the encouraging clinical evidence that spontaneous growth was producing sufficient cutaneous redundancy on its own. Surgeons serially assessed the pinch-laxity and dermal mobility of the lateral gluteal and flank skin relative to fixed skeletal landmarks, including the sacrococcygeal junction and the posterior superior iliac spines. Robust capillary refill times of under two seconds and the absence of scar tethering confirmed healthy microvascular perfusion, and by the time of surgery the natural tissue creep had generated enough lateral skin folds to permit primary local flap reconstruction without any synthetic prostheses.

Neuroimaging proved decisive in mapping the twins’ shared anatomy. A computed tomography scan with three-dimensional reconstruction at three months of age revealed that each twin had an independent, anatomically normal cervical, thoracic, and lumbar spine, with no osseous bridging and skeletal contact limited to the lower sacrococcygeal region. Magnetic resonance imaging of the pelvis then delivered the finding that defined the case: the sacrum was deficient in both infants, and the distal spinal cords and dural sacs converged and fused near the sacrococcygeal level within the soft tissue bridge. The thoracic and abdominal visceral compartments remained entirely separate. This combination of shared spinal cord and shared dura is exceptionally rare in pygopagus twins and dramatically raises the stakes of separation, since any misjudgment during cord division risks permanent neurological injury to one or both children. After reviewing the imaging, the surgical board scheduled the operation, though it was postponed once more when Twin A developed pneumonia, ultimately taking place six months after birth, which coincidentally aligned with the internationally recommended window of four to twelve months for planned elective separation.

The operation itself showcased how surgical precision can substitute for technology. Because advanced intraoperative neurophysiological monitoring, including somatosensory evoked potentials, motor evoked potentials, and electromyographic nerve root stimulation, was unavailable, neural preservation depended entirely on high-magnification operating microscopy and anatomical landmarks. The infants were positioned in a synchronized lateral decubitus position, and the team designed a modified curvilinear zigzag, interlocking S-pattern incision over the posterior bridge, a geometry chosen to distribute skin tension evenly, prevent straight-line scar contracture over the sacrum, and optimize flap interdigitation for each twin. Subcutaneous flaps were elevated down to the paraspinal fascia, and the sacrococcygeal junction served as the principal anchor for the exposure. Under high-power magnification, the fused thecal envelope was incised longitudinally along the midline raphe, opening the common dural chamber.

Inside the shared thecal sac, the surgeons traced each nerve root systematically, both proximally toward its origin on the cord and distally toward its corresponding neural foramen, confirming bilaterally and visually that every root belonged unequivocally to its respective infant before any division. With gentle blunt micro-dissection and continuous saline irrigation, the conjoined lower cord elements were separated without sacrificing functioning neural tissue from either twin, and the thecal sac was partitioned into two distinct envelopes. Each baby was then moved to a separate operating table, where the team repaired the dura under the microscope using 6-0 polypropylene sutures in a watertight fashion, reinforced the closure with a fascial layer, and confirmed the absence of cerebrospinal fluid leakage with a Valsalva maneuver before closing the wounds in layers. Cerebrospinal fluid leakage is a historically frequent and dangerous complication in pygopagus separations involving dural sharing, making this watertight closure one of the operation’s most consequential technical victories.

The postoperative course was largely uneventful. Apart from a bout of pneumonia in Twin B on the third day, which was treated successfully, neither infant developed surgical site infections, wound dehiscence, flap necrosis, or cerebrospinal fluid leaks. Detailed neurological examinations before discharge revealed active, symmetric, spontaneous movements of both lower extremities in each infant, normal muscle tone across the hip flexors, quadriceps, and gastrocnemius muscles, and brisk, bilaterally equal deep tendon reflexes. Sensory withdrawal responses were intact across all lumbar and sacral dermatomes from L1 to S3, and both twins displayed robust anal wink reflexes, confirming preservation of the S2 to S4 sacral autonomic and pudendal pathways that govern bowel and bladder control. Both infants demonstrated normal spontaneous fecal evacuation and independent voluntary voiding. They were released on the twelfth postoperative day with basic vitamin supplements and are now reportedly healthy and living independently.

The outcome carries weight well beyond this single hospital. Survival rates for conjoined twins after separation range from roughly 16.7 to 50 percent depending on the type of operation and whether it is elective or emergency, and mortality climbs sharply when neurological structures are shared, since it is exceptionally difficult for both twins to survive the division of a joined spinal cord. The authors of the report are candid about the limitations of their approach: nutritional and skin assessments relied on clinical expertise and biochemical parameters rather than validated scoring tools or perfusion devices, no real-time electrophysiological feedback was available during cord division, and follow-up assessments were clinical rather than urodynamic or electrodiagnostic. Even so, the case demonstrates that three surgical strategies, fixed skeletal anchoring, stepwise magnified micro-dissection, and individual rootlet verification before dural division, can substitute meaningfully for expensive neuromonitoring. For surgical teams across the developing world, where conjoined twin separations are often deemed impossible without technology-rich environments, this successful delayed elective separation offers both a practical roadmap and a compelling proof of concept.

Subject of Research: Delayed elective surgical separation of pygopagus conjoined twins with shared spinal cord and dura

Article Title: Successful Delayed Elective Separation of Pygopagus Conjoined Twins With Shared Spinal Cord and Dura in a Resource‐Limited Setting: A Case Report

Article References: Wahid, Z. U. M., Chowdhury, S. I., Islam, N., & Mifty, S. K. (2026). Successful Delayed Elective Separation of Pygopagus Conjoined Twins With Shared Spinal Cord and Dura in a Resource‐Limited Setting: A Case Report. Clinical Case Reports, 14(10), Article e73657. https://doi.org/10.1002/ccr3.73657

Image Credits: AI Generated

DOI: 10.1002/ccr3.73657

Keywords: conjoined twins, pygopagus, spinal cord, separation surgery, neurosurgery, pediatric surgery, microsurgery, resource-limited settings, dural repair, nutritional optimization, case report, tissue expansion

The study, led by researchers at the Southern University of Science and Technology, began with a deceptively simple observation. When mice received a spinal injection of morphine, the drug rapidly increased phosphorylation, the biochemical switch that activates EphB1 receptors, in both the dorsal root ganglia, clusters of sensory neurons outside the spinal cord, and the spinal cord itself. In the dorsal root ganglia, morphine also raised levels of ephrinB2, the ligand that binds and switches on EphB1. That increase, the researchers showed, depended on the mu-opioid receptor, the very molecule through which morphine produces pain relief. In other words, morphine appears to trigger its own weakening by activating a signaling pathway that sits alongside its primary target.

To test whether EphB1 signaling actually interferes with pain relief, the team administered ephrinB2-Fc, a laboratory reagent that activates EphB1 receptors, directly into the spinal canal of mice. Even at a low dose that did not alter pain sensitivity on its own, the activator significantly blunted the analgesic effect of morphine in both the tail-flick and hot-plate tests, standard measures of pain response in rodents. Crucially, the dampening effect was selective. EphrinB2-Fc interfered with the analgesia produced by DAMGO, a drug that specifically activates mu-opioid receptors, but left untouched the effects of DPDPE and U69593, which act on the delta and kappa opioid receptor subtypes. That selectivity told the researchers that EphB1 signaling is functionally intertwined with the mu-opioid receptor in particular, not with opioid signaling in general.

The next step was to remove EphB1 and see what happened. Using genetic tools, the team created mice lacking EphB1 receptors specifically in neurons that express Vglut2, a marker of excitatory glutamatergic neurons found both in the dorsal root ganglia and in the spinal dorsal horn, the region where pain signals from the body are processed. When these mice received morphine, the analgesic effect was markedly stronger than in normal animals, while baseline pain sensitivity remained unchanged. The enhancement again applied only to DAMGO, reinforcing the link to mu-opioid receptors. The same pattern held in mouse models of disease: in animals with partial sciatic nerve ligation, a model of neuropathic pain, and in animals implanted with lung carcinoma cells in the tibia, a model of bone cancer pain, deleting EphB1 significantly strengthened morphine’s ability to reverse mechanical allodynia and thermal hyperalgesia.

To separate the peripheral and central contributions, the researchers ran parallel experiments. Crossing mice with an inducible Cre driver called Advillin allowed them to delete EphB1 exclusively in dorsal root ganglion neurons, and this too enhanced morphine analgesia. Meanwhile, injecting a Cre-expressing virus directly into the lumbar spinal cord deleted the receptor only in dorsal horn Vglut2-positive neurons, with the same result. Imaging studies supported the anatomical logic: EphB1 and the mu-opioid receptor are co-expressed in small-diameter sensory neurons, on sensory axon terminals, and in excitatory interneurons of the dorsal horn, where roughly thirty percent of Vglut2-positive neurons carried both Ephb1 and Oprm1, the gene encoding the mu-opioid receptor. Inhibitory neurons showed far less overlap.

Electrophysiology then revealed how removing EphB1 changes the behavior of individual neurons. Opioids quiet pain pathways partly by shutting down voltage-gated calcium channels in sensory neurons, which reduces the release of pain-signaling neurotransmitters. In cultured dorsal root ganglion neurons lacking EphB1, DAMGO suppressed calcium influx, measured by calcium imaging, and calcium currents, measured by patch clamp, more powerfully than in control neurons. In spinal cord slices, DAMGO’s inhibition of spontaneous excitatory synaptic currents in dorsal horn Vglut2-positive neurons was deeper without EphB1, and the drug also produced larger outward potassium currents, a hallmark of opioid receptor activation, in those neurons. Every measure pointed the same way: without EphB1, mu-opioid receptors simply work better.

The mechanism behind that improvement turned out to be receptor trafficking. When mu-opioid receptors are phosphorylated at a specific amino acid, serine 375, by enzymes called G protein-coupled receptor kinases, the adaptor protein beta-arrestin is recruited and drags the receptor off the cell surface into the interior of the cell, where it can no longer respond to morphine. The researchers found that activating EphB1 with ephrinB2-Fc pushed mu-opioid receptors out of the membrane and into the cytoplasm of cultured cells, even without any opioid drug present, and amplified the internalization triggered by DAMGO. EphB1 activation also increased phosphorylation of the receptor at serine 375, both in cell culture and in the dorsal root ganglia and spinal cords of living mice. Conversely, deleting EphB1 blunted that phosphorylation in response to DAMGO, including in the neuropathic and cancer pain models.

The missing link was GRK2, one of the G protein-coupled receptor kinases. Co-immunoprecipitation experiments showed that EphB1 receptors physically associate with GRK2 in the dorsal root ganglia and spinal cord, and that all three proteins, EphB1, GRK2, and the mu-opioid receptor, form a complex. GRK2 is heavily expressed in the same nociceptor populations that carry EphB1 and the opioid receptor. When EphB1 was activated, GRK2 became phosphorylated on tyrosine residues, a modification known to boost the enzyme’s catalytic activity, and GRK2 bound more tightly to the mu-opioid receptor. Paroxetine, an antidepressant already approved by the US Food and Drug Administration that happens to be a potent and selective GRK2 inhibitor, completely reversed the EphB1-driven phosphorylation of the opioid receptor at serine 375 and blocked the receptor internalization that followed. That result anchors the entire pathway: EphB1 activates GRK2, GRK2 phosphorylates the mu-opioid receptor, and the receptor disappears from the cell surface.

The implications reach well beyond a single experiment. Because GRK2 helps terminate signaling for hundreds of G protein-coupled receptors, the ephrin-Eph system may turn out to be a broad regulator of GPCR trafficking in many contexts, a possibility the authors flag as an exciting direction for future work. More immediately, the study offers a concrete strategy against opioid tolerance: if blocking EphB1 signaling, or inhibiting GRK2 with drugs such as paroxetine, keeps mu-opioid receptors on the neuronal surface, patients might obtain durable pain relief at lower opioid doses, reducing both escalation and overdose risk. The findings also add to a growing body of evidence that receptor tyrosine kinases, including the insulin receptor and the epidermal growth factor receptor, crosstalk with opioid receptors and shape analgesia, dependence, and reward. Translating the mouse results into the clinic will require much more work, but the identification of a druggable node in the tolerance machinery gives researchers a clear place to start.

Subject of Research: EphB1 receptor regulation of mu-opioid receptor trafficking and morphine antinociception

Article Title: EphB1 Receptor Blockade Augments Morphine Antinociception via Inhibiting GRK2‐Mediated µ‐Opioid Receptor Internalization

Article References: EphB1 Receptor Blockade Augments Morphine Antinociception via Inhibiting GRK2‐Mediated µ‐Opioid Receptor Internalization. (n.d.). https://doi.org/10.1002/advs.78099

Image Credits: AI Generated

DOI: 10.1002/advs.78099

Keywords: EphB1, morphine, opioid tolerance, mu-opioid receptor, GRK2, receptor internalization, dorsal root ganglion, spinal cord, pain, analgesia, ephrinB2, paroxetine

The scale of the problem is striking. Multiple sclerosis affects more than 2.9 million people worldwide, and spinal cord lesions are present on up to 85 percent of cord MRI scans in newly diagnosed patients. As many as 76 percent of people with relapsing-remitting MS and 90 percent of those with progressive disease carry at least one cord lesion when the entire cord is imaged. Yet a 2026 systematic review cited in the paper found that of 291 MS clinical trials, only eight, roughly 2.7 percent, planned to include spinal cord MRI metrics as an outcome, and just three ever published those results. None showed a significant effect on cord atrophy or lesion number compared with placebo.

Why has the cord been so hard to study? The review describes a perfect storm of technical obstacles. The cord is small, demanding thin image slices of one to three millimetres to capture lesions reliably. It is encased in bone and bathed in cerebrospinal fluid that pulses rhythmically with every heartbeat, creating motion artefact. Susceptibility differences between cord, fluid, bone and air distort the magnetic field, and minor inconsistencies in slice positioning between scans can introduce spurious apparent change over time. Krieger famously likened standard clinical cord MRI to cave paintings, a vivid indictment of images whose resolution and signal-to-noise ratio lag far behind what is routinely achieved in the brain.

Despite these limitations, the prognostic evidence is unambiguous. Spinal cord lesions predict conversion to MS in people with radiologically isolated syndrome, and patients whose first clinical event involves the cord convert to definite MS faster than those without cord involvement. Total cord lesion volume at diagnosis correlates with later disability measured by the Expanded Disability Status Scale, the Nine-Hole Peg Test and the Timed 25-Foot Walk. Crucially, both lesion volume and lesion number at diagnosis are associated with progression independent of relapse activity, the insidious worsening known as PIRA that unfolds even when inflammatory attacks are suppressed. This suggests that standard monitoring protocols, which focus heavily on the brain, miss much of the biology driving long-term disability.

Atrophy tells an even sharper story. Healthy adults lose spinal cord cross-sectional area at a physiological rate of about 0.06 percent per year; people with MS lose it at roughly 1.78 percent per year. In a retrospective study of more than 360 people with relapsing-remitting MS, those who later converted to secondary progressive disease showed cord atrophy of 2.19 percent per year over four years, versus 0.88 percent in those who did not. Cord cross-sectional area correlates with disability more closely than brain atrophy does, and grey matter loss within the cord, which is greater in progressive disease, shows even stronger associations with clinical impairment than whole-cord measures.

The diagnostic stakes have risen with the 2024 revisions to the McDonald criteria. The cord now counts as one of five anatomical topographies for demonstrating dissemination in space, and in suspected primary progressive MS, just two cord lesions are sufficient to establish that criterion without a second topography. The criteria also caution that in patients over fifty or with significant vascular risk factors, cord lesions should be sought before attributing white matter changes to small-vessel ischaemia. Lesion morphology matters too: MS cord lesions are typically short, peripheral, cigar-shaped on sagittal views and wedge-shaped axially, features that help separate MS from neuromyelitis optica spectrum disorder and MOG antibody disease, which favour longitudinally extensive, central or grey-matter-predominant lesions, including the so-called H sign in MOGAD.

The differential diagnosis extends well beyond other inflammatory diseases. Spinal cord infarction produces the classic owl-eyes or pencil-like patterns on MRI, while spinal dural arteriovenous fistulas can mimic progressive MS with slowly worsening myelopathy, and missing one can be devastating, particularly since steroids may worsen the congested cord. Compressive spondylotic myelopathy, vitamin B12 and copper deficiency with its inverted dorsal V sign, infectious myelitides, neurosarcoidosis with its trident sign, and even rare pegivirus-associated cord tractopathy all crowd the differential. The review underscores that accurate pattern recognition on cord MRI is a diagnostic safety net as much as a research tool.

On the acquisition side, consensus is crystallising. The 2024 MAGNIMS-CMSC-NAIMS recommendations call for whole-cord imaging with two complementary sagittal sequences, gapless T2 fast spin echo, STIR, PSIR or MP(2)RAGE at slice thickness under three millimetres, plus one axial sequence, and explicitly discourage FLAIR for cord lesion detection. Notably, moving from 1.5 to 3 Tesla confers no overall advantage for cord lesion detection, because field inhomogeneity, motion sensitivity and energy deposition offset the signal gains. Newer three-dimensional sequences such as phase-sensitive inversion recovery have demonstrated greater sensitivity for cervical cord lesions than conventional two-dimensional STIR, and ultra-high-field 7 Tesla imaging has boosted lesion detection by a reported 52 percent while revealing cord analogues of the brain’s central vein sign and paramagnetic rim lesions, though these remain research tools for now.

The most forward-looking section of the review surveys quantitative techniques edging toward the clinic. Diffusion tensor imaging reveals reduced fractional anisotropy and elevated diffusivity extending into normal-appearing cord tissue, correlating with disability even in patients with low lesion burdens. Magnetisation transfer ratio, sensitive to myelin integrity, is reduced across the cervical cord of recently diagnosed patients even when visible lesions are excluded, hinting at a biomarker for PIRA. Myelin water imaging fell by more than ten percent over two years in primary progressive MS, and proton spectroscopy shows N-acetyl-aspartate reductions signalling axonal compromise before atrophy becomes measurable. Emerging chemical exchange saturation transfer and sodium MRI point to diffuse biochemical disruption beyond focal lesions. Artificial intelligence is beginning to automate cord and lesion segmentation through tools such as the open-source Spinal Cord Toolbox, though no model yet supports reliable longitudinal lesion tracking, and none has achieved regulatory approval as a clinical device.

The authors’ conclusion is pragmatic. Every patient should receive high-quality MRI of the entire spinal cord at diagnosis, and because a meaningful fraction of cord lesions are asymptomatic, they propose routine whole-cord imaging every two to three years, an expert opinion offered in the absence of formal consensus, to catch subclinical activity before irreversible disability accumulates. They also urge trial designers to incorporate cord lesion burden and atrophy as endpoints, particularly in progressive disease cohorts where cord pathology dominates the clinical picture. The evidence base still suffers from small, single-centre, cross-sectional studies and heterogeneous acquisition protocols, and most advanced biomarkers remain confined to research settings. But the direction of travel is clear: the spinal cord, long relegated to cave paintings, is being repainted in high resolution, and what it reveals may reshape how MS is diagnosed, monitored and treated.

Subject of Research: Spinal cord MRI biomarkers for diagnosis and progression monitoring in multiple sclerosis

Article Title: Spinal cord imaging in multiple sclerosis: from diagnosis to disease progression

Article References: Spinal cord imaging in multiple sclerosis: from diagnosis to disease progression. (n.d.). https://doi.org/10.1007/s00415-026-14122-3

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14122-3

Keywords: multiple sclerosis, spinal cord, MRI, spinal cord atrophy, McDonald criteria, progression independent of relapse activity, demyelination, magnetisation transfer, diffusion MRI, myelin water imaging, artificial intelligence, disease-modifying therapy

The research team, led by Yuanxuan Xia of the Department of Neurosurgery at Johns Hopkins University School of Medicine, screened 1,401 patients who underwent spinal MRI between 2020 and 2025 at a tertiary academic center. From that pool, only 69 patients met the strict inclusion criteria: they had intramedullary lesions, which arise within the spinal cord itself, or leptomeningeal lesions, which seed the delicate membranes surrounding the cord, and they had a primary cancer that originated outside the central nervous system. Patients whose tumors began in the brain or spinal cord, and those with non-cancer diagnoses, were excluded to ensure the cohort represented true metastatic spread from systemic disease.

The composition of the cohort reflects the broader epidemiology of CNS metastasis. Lung cancer accounted for 33.3 percent of primary tumors, followed closely by breast cancer at 31.9 percent, with the remainder drawn from other solid malignancies. Only 11.6 percent of patients underwent surgery for their intradural disease, underscoring how often these lesions are managed with radiation, systemic therapy, or palliative care rather than operative intervention. The anatomical distribution of disease at first detection was striking: 55.1 percent of patients had cervical involvement, 65.2 percent thoracic, and 76.8 percent lumbar, suggesting that tumor cells descending through the cerebrospinal fluid tend to accumulate in the lower reaches of the thecal sac, where gravity and CSF flow patterns favor deposition.

Perhaps the most consequential finding of the study is its reconstruction of the metastatic timeline. Among the 69 patients, the median interval from primary cancer diagnosis to any metastasis was just 0.5 months, with an interquartile range spanning 0 to 6.7 months, indicating that systemic dissemination often begins almost immediately, sometimes even before the primary tumor is detected. Spread to the brain followed at a median of 14.9 months, while seeding of the osseous spine, the bony vertebrae surrounding the cord, occurred at a median of 19.4 months. Intradural spinal involvement, by contrast, was a distinctly late event, arriving at a median of 29.5 months after the primary diagnosis, with an interquartile range of 14.0 to 52.6 months.

This chronology carries important biological implications. It suggests that tumor cells capable of surviving in the cerebrospinal fluid and invading the intradural compartment represent a late-arising, highly selected subclone within the evolving cancer population. The intradural space is immunologically and pharmacologically distinct from the rest of the body: it is sheltered by the blood-spinal cord and blood-brain barriers, bathed in CSF, and relatively inaccessible to many conventional chemotherapies. Cells that successfully colonize it must acquire a suite of adaptations, from altered adhesion molecules to enhanced survival signaling in a nutrient-poor environment, and the long delay before their emergence is consistent with the gradual accumulation of these traits over successive rounds of dissemination and selection.

The prognosis attached to this late stage is sobering. Within a median follow-up of 42.0 months after primary cancer diagnosis, the mortality rate in the cohort reached 87.0 percent. That figure, drawn from an interquartile range of 20.6 to 72.9 months of follow-up, reflects both the aggressiveness of the underlying cancers and the limited therapeutic arsenal available once disease has penetrated the intradural compartment. Leptomeningeal metastasis in particular has long been associated with poor outcomes across solid tumors, and the present data reinforce the sense that intradural involvement marks an advanced chapter in the metastatic story rather than an isolated complication.

Yet the study also uncovered a genuine therapeutic opening in its molecular analysis. Targetable mutations, alterations in genes for which approved or investigational targeted drugs exist, were identified in 46.4 percent of primary lesions. Patients whose tumors carried such biomarkers trended toward improved overall survival, with a median of 51.7 months compared with 30.1 months for those without actionable alterations, a difference that approached but did not reach conventional statistical significance at p equal to 0.072. The critical distinction emerged when the researchers separated patients who actually received targeted therapies from those who did not. Among patients with actionable biomarkers who qualified for and received matched targeted treatment, median overall survival rose to 56.2 months, significantly better than the 31.2 months observed in those who did not receive such therapy, with p equal to 0.029.

That survival gap, though drawn from a small and retrospective cohort, aligns with a growing body of evidence that molecular profiling of CNS metastases can change the trajectory of disease. Prior work has shown that genomic data obtained from spinal metastatic tumor samples are clinically reliable, and recent multicenter studies of leptomeningeal metastasis in non-small cell lung cancer have demonstrated that cerebrospinal fluid circulating tumor DNA profiling can stratify risk and guide matched treatment. The Johns Hopkins findings extend this logic to the intradural spinal compartment specifically, arguing that nearly half of patients who develop disease there carry druggable alterations detectable in their primary tumors.

The study’s authors conclude that regular molecular characterization and sequencing of the intradural space, for example through CSF liquid biopsy, could have a clinically meaningful impact on these patients. Liquid biopsy of cerebrospinal fluid offers a minimally invasive window into the genetic landscape of tumors sheltering behind the blood-CNS barriers, capturing shed DNA that peripheral blood draws often miss. As sequencing technologies become smaller, cheaper, and faster, the prospect of routinely sampling CSF in patients with known metastatic disease becomes increasingly practical, potentially allowing clinicians to detect intradural seeding earlier in the cascade and to select targeted agents before neurological function is compromised.

The broader significance of the work lies in its framing of intradural spinal metastasis not as a random complication but as a definable, time-stamped stage within the metastatic cascade. By quantifying when in the disease course these lesions appear, where they settle along the spinal axis, and what molecular vulnerabilities they inherit from their primary tumors, the study provides clinicians with a roadmap for surveillance and a rationale for aggressive molecular workup. For a patient population in which median survival is measured in years rather than decades, and in which nearly nine in ten patients do not survive beyond the median follow-up window, any intervention that adds months of meaningful life, as targeted therapy appears to do, represents progress worth pursuing. The challenge ahead is to translate this retrospective portrait into prospective strategies: earlier CSF-based screening for high-risk patients, systematic sequencing of both primary tumors and intradural deposits, and clinical trials of targeted and CNS-penetrant agents designed specifically for this late but biologically distinct frontier of cancer spread.

Subject of Research: Clinical course, dissemination timing, and molecular features of intradural spinal metastasis in patients with systemic cancer

Article Title: Characterizing intradural spinal metastasis in the metastatic cascade: clinical course, dissemination timing, and molecular features in 69 patients

Article References: Characterizing intradural spinal metastasis in the metastatic cascade: clinical course, dissemination timing, and molecular features in 69 patients. (n.d.). https://doi.org/10.1007/s11060-026-05794-y

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05794-y

Keywords: intradural spinal metastasis, leptomeningeal metastasis, metastatic cascade, spinal cord, cerebrospinal fluid, liquid biopsy, targeted therapy, lung cancer, breast cancer, molecular biomarkers, overall survival, neuro-oncology

Interoception, the central concept in the new analysis, is commonly defined as the process by which the nervous system senses, interprets, and integrates signals arising from within the body. Heartbeat, breathing rhythm, temperature, visceral tension, and the constellation of internal sensations that color every waking moment all travel upward through dedicated neural channels. The authors emphasize that a substantial portion of this traffic passes through the spinal cord, forming what they call spinal interoceptive pathways. These pathways deliver continuous updates about bodily states to a distributed interoceptive system in the brain, where they inform and constrain predictive models of what the body will experience next. In this framework, the brain is not a passive receiver but an active forecaster, constantly generating predictions about upcoming bodily states and comparing them against incoming signals.

The predictive dimension is where interoception connects most directly to emotion. According to the theoretical models reviewed by Romo-Nava and his colleagues, the brain uses its predictions about bodily states to adjust physiology through descending projections, a closed-loop architecture that maintains homeostasis—the finely tuned internal equilibrium on which survival depends. Emotional experience, in this view, is inseparable from the quality and accuracy of the bodily signals feeding the loop. When the ascending traffic is distorted, dampened, or amplified, the brain’s predictive models drift out of alignment with actual bodily conditions, and the subjective result may be the persistent malaise, heaviness, and dysphoria characteristic of depression. The authors argue that dysregulated signaling in spinal interoceptive pathways and the resulting interoceptive processing errors may play a genuine role in the depressive syndrome rather than being a mere byproduct of it.

What makes this proposal more than a philosophical reframing is its therapeutic implication. If the spinal cord carries a continuous stream of body-to-brain information that shapes mood, then the spinal cord is a physically accessible target. Unlike dispersed cortical networks buried deep within the brain, spinal pathways run through an anatomically well-mapped structure that clinicians already know how to stimulate, record from, and modulate. Neuromodulation technologies—devices and techniques that alter nerve activity through targeted electrical or other stimulation—are routinely applied to the spinal cord in other areas of medicine, most famously for pain management. The perspective article argues that the same general strategy could, in principle, be redirected toward the interoceptive traffic that informs emotional state, opening a novel route for studying and eventually treating major depressive disorder.

The scale of the unmet need gives the proposal urgency. Major depressive disorder affects hundreds of millions of people worldwide, and a large fraction of patients do not achieve lasting relief from available medications and psychotherapies. Existing neuromodulation treatments for depression, such as transcranial magnetic stimulation and implanted brain stimulation devices, work from the top of the loop, targeting the brain directly. An approach that intervenes from the bottom of the loop, at the spinal gateway where bodily signals enter, would represent a fundamentally different mechanistic strategy—one that could complement rather than compete with brain-focused therapies. The authors position spinal interoceptive modulation not as a replacement for existing care but as an additional lever on a system that current treatments leave largely untouched.

Yet the researchers are candid about a major obstacle: a substantial knowledge gap. Despite the theoretical appeal of the framework, the role of spinal interoceptive pathways in major depressive disorder remains poorly characterized. It is not yet established which specific spinal mechanisms are altered in depression, how those alterations propagate to the distributed interoceptive system in the brain, or how changes in spinal signaling correlate with changes in mood. The perspective article frames this gap as the central scientific challenge of the field and argues that closing it requires deliberate experimentation rather than assumption. The authors present their work as emerging evidence supporting the exploration of spinal interoceptive pathways as novel and feasible targets—emphasizing both words, novelty and feasibility, to signal that the approach is grounded in existing technology while pointing toward unexplored biology.

A key methodological problem the article confronts is how to prove that a spinal intervention is actually doing what it claims to do. In clinical neuroscience, this is the problem of target engagement: demonstrating that a treatment measurably modifies the biological mechanism it is designed to influence. Without reliable markers of spinal interoceptive target engagement, any clinical trial of spinal neuromodulation for depression would be flying blind, unable to distinguish between a therapy that failed because the mechanism was wrong and one that failed because the delivery was imprecise. The authors therefore devote significant attention to candidate experimental models and the critical next steps needed to identify markers that would show whether a given intervention is genuinely changing spinal interoceptive signaling. Such markers would be the measurement backbone for future studies, allowing researchers to connect stimulation parameters to physiological changes and physiological changes to clinical outcomes.

The research program described in the article is already backed by institutional investment. The work was supported by the Lindner Center of Hope and the University of Cincinnati, as well as by the National Institute of Mental Health, which funded the effort in part through grant 1R61MH133770-01A1. The breadth of the author team reflects the interdisciplinary demands of the project: the collaboration includes psychiatrists, neurologists, neurosurgeons, a biostatistician, and interoception specialists from the Laureate Institute for Brain Research and UCLA’s Semel Institute for Neuroscience and Human Behavior. Bringing together expertise in spine-level intervention, brain imaging, psychiatric assessment, and trial design is a prerequisite for a program that spans the length of the neuraxis—from peripheral bodily sensors through spinal relay stations to cortical interoceptive networks.

The broader scientific context makes the timing of this proposal notable. Across neuroscience, interoception has moved from a niche topic to a central framework for understanding psychiatric illness, with conditions including anxiety, eating disorders, and depression increasingly interpreted as disorders of bodily signal processing. Predictive processing models of the brain have given the field a common theoretical language, describing perception and emotion as consequences of prediction and prediction error rather than simple stimulus response. The spinal cord, in this emerging picture, is no longer a mere cable between brain and body but an active processing station that shapes the information it transmits. The Romo-Nava perspective extends that shift by insisting that the clinical implications run in both directions: just as the brain constrains the body through descending projections, the body constrains the brain through ascending spinal channels, and either side of the loop can be an intervention point.

If the research program succeeds, the consequences could extend well beyond depression. Spinal interoceptive pathways plausibly contribute to the physical symptoms that accompany many psychiatric conditions—chronic pain, fatigue, autonomic dysregulation—and a validated method for measuring and modulating spinal interoceptive signaling could illuminate all of them. For now, the authors’ contribution is a roadmap: a reasoned case that the spinal cord is a feasible, mechanistically motivated target for depression research, an honest account of what remains unknown, and a set of candidate models and engagement markers to guide the experiments ahead. As the field confronts the limits of treatments aimed solely at the brain, the message of this perspective is that mood may be built, in part, from signals that begin their journey in the body—and that the gateway through which those signals travel may one day become a place where depression is treated.

Subject of Research: The role of spinal interoceptive pathways in major depressive disorder and their potential as neuromodulation targets

Article Title: Spinal interoceptive pathways as therapeutic targets in depression

Article References: Romo-Nava, F., Awosika, O. O., Phan, P., Basu, I., Liu, J. C., Charnas, C., Georgiev, G., Mori, N. N., Welge, J., Blom, T., Fleck, D. E., Cao, X., Khalsa, S., Paulus, M., & McElroy, S. L. (2026). Spinal interoceptive pathways as therapeutic targets in depression. Discover Mental Health. https://doi.org/10.1007/s44192-026-00597-z

Image Credits: AI Generated

DOI: 10.1007/s44192-026-00597-z

Keywords: interoception, spinal cord, major depressive disorder, neuromodulation, predictive processing, homeostasis, psychiatry, spinal interoceptive pathways, target engagement, neuroscience, Spinal, interoceptive

The significance of the approach lies in what it does not do. Conventional genome editing tools such as CRISPR-Cas9 nucleases work by cutting both strands of the DNA double helix, creating a break that the cell must then repair. That repair process is error-prone and can introduce unintended changes, and double-strand breaks in neurons raise serious safety concerns for any clinical application. Adenine base editors, by contrast, act more like a molecular pencil eraser and pencil in one. They chemically convert a single DNA letter, an adenine, into guanine without severing the backbone of the double helix. For a disease caused by exactly one incorrect nucleotide, that precision is precisely what is needed, since it allows the disease-causing change to be rewritten back to its healthy sequence while leaving the rest of the genome untouched.

The HMSN-P mutation presented a particularly thorny therapeutic puzzle. Unlike disorders that can be managed by simply dialing down the activity of a faulty gene, this mutation appears to damage cells through several mechanisms at once. The mutant TFG protein misfolds and clumps into abnormal aggregates that poison the cell from within, while the disruption of the gene’s normal housekeeping functions likely adds a second, independent layer of injury. Suppressing expression of the mutant gene would eliminate the toxic aggregates but would also deprive neurons of a protein they need to function. The only strategy that could address both disease mechanisms simultaneously was to correct the mutation itself, restoring a normal protein and normal gene activity in one step. That reasoning drove the team toward base editing rather than gene silencing or gene replacement.

To find the right tool, the researchers started with cells from an actual patient. Using induced pluripotent stem cell technology, they reprogrammed the patient’s cells back into a stem-like state and then compared several candidate adenine base editors for their ability to fix the HMSN-P mutation. After screening the options, they identified an editor that combined high correction efficiency with strong specificity, minimizing the risk of off-target edits elsewhere in the genome. The editing system was then packaged into adeno-associated virus vectors, the workhorse delivery vehicles of experimental gene therapy, and engineered so that the vectors would preferentially target cells within the spinal cord, where the motor neurons at the heart of the disease reside.

A crucial piece of the work involved building a better animal model. The team generated mice carrying the human TFG mutation, and these animals developed a disease strikingly reminiscent of the human condition: progressive motor dysfunction, loss of motor neurons, degeneration of nerve fibers, and activation of inflammatory support cells in the nervous system. When the researchers treated these mice with the base-editing therapy, the results were striking. The mutant allele was successfully corrected in the spinal cord, and the treated animals fared markedly better than their untreated counterparts. Disease onset was delayed, motor performance improved, motor neurons and their axons were preserved, and survival was significantly extended. For a disorder with no existing treatment, the demonstration that correcting a single DNA letter could meaningfully alter the disease trajectory represents a conceptual turning point.

The team wanted to understand not just whether the therapy worked, but how. They turned to single-cell transcriptomic analysis, a technique that profiles the gene activity of individual cells within a tissue, and examined the spinal cords of treated and untreated animals. The analysis revealed that the treatment dampened disease-associated immune activation in microglia, the resident immune cells of the central nervous system. Genes involved in antigen presentation and inflammatory signaling, which are abnormally revved up in neurodegenerative disease, were partially normalized after editing. This finding suggests that correcting the genetic error does more than protect the neurons directly; it also improves the surrounding cellular environment, easing the inflammatory milieu that can otherwise accelerate neuronal death. Neurodegeneration, in other words, is not solely a story about sick neurons, and a therapy aimed at the root genetic cause can ripple outward to calm the entire ecosystem of the damaged spinal cord.

Because mouse models do not always translate cleanly to human biology, the investigators also tested the therapy in human neuromuscular organoids grown from patient-derived iPS cells. These three-dimensional tissue cultures reproduce important features of the human disease, including the abnormal accumulation of TFG protein aggregates and elevated neuronal death. When the base-editing system was applied to these organoids, protein aggregation dropped markedly and neuronal loss was suppressed. The results demonstrated, in tissue of human origin, that the editing strategy can counter the core pathological hallmarks of HMSN-P rather than merely modifying downstream symptoms, strengthening the case that the approach targets the disease at its source.

The study, published as a peer-reviewed research article, combines several of the most powerful technologies in modern biomedical science: high-fidelity genome editing, patient-derived stem cells, a newly engineered animal model, single-cell genomics, and human organoid culture. Each component played a distinct role, from establishing that the mutation could be corrected efficiently in human cells, to proving that correction translates into survival benefit in a living organism, to illuminating the molecular changes that follow treatment. Together they paint a coherent picture of a precision therapy that works at multiple levels, from the DNA sequence itself to the inflammatory behavior of immune cells to the survival of neurons and the lifespan of the animal.

Important caveats remain. Comprehensive safety evaluations, including rigorous assessment of off-target editing across the genome and the safety of viral delivery to the spinal cord, will be required before any attempt at clinical application. HMSN-P is rare, which presents its own challenges for developing and testing therapies intended for a small patient population. Yet the broader implications extend well beyond this single disorder. Inherited motor neuron diseases share many features with HMSN-P, and a growing number of them have now been linked to specific point mutations. The demonstration that a single pathogenic nucleotide can be corrected in the nervous system, with measurable functional benefit, establishes a template that could in principle be adapted to other genetic neurodegenerative conditions. For a field in which most therapies can only manage symptoms, the prospect of rewriting the genetic error at the origin of disease offers something fundamentally different, and for the patients and families affected by HMSN-P, it offers the first credible hope of changing the course of the illness.

Subject of Research: Adenine base editing to correct a TFG gene mutation causing hereditary motor neuron degeneration, tested in mouse models and patient-derived iPS cell organoids.

Article Title: Countering motor neuron degeneration with base editing

Article References: Countering motor neuron degeneration with base editing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: base editing, motor neuron disease, TFG gene, HMSN-P, iPS cells, gene therapy, adeno-associated virus, microglia, neurodegeneration, organoids, precision medicine, spinal cord